Join our Advisory Board
The Healthcare Advisory Board (HAB) for both Onco’Zine and ADC Review / Journal of Antibody-drug Conjugates is comprised of physicians and industry experts/Key Opinion Leaders (KOL) from a broad range of backgrounds and expertise. Accomplished in areas including clinical oncology and hematology practice innovation and management, public policy, professional advocacy and education, our Healthcare Advisory Board members are able to combine their passion and know-how for patient care to create tremendous value for all members of our international network.
Our Healthcare Advisory Board (HAB) members are actively managing successful clinical practices, teaching at major universities and hospitals, holding senior management positions at medical associations, pharmaceutical companies, governmental agencies and major insurance companies, and advising policymakers on major issues facing oncologists and hematologists on the front lines of healthcare delivery today.
Our Healthcare Advisory Board brings an impressive level of healthcare experience to our publication, enabling us to offer innovation, education, advocacy and best practices to our members
Our Healthcare Advisory Board brings an impressive level of healthcare experience to our publication, enabling us to offer innovation, education, advocacy and best practices to our members. Each HAB member is involved in helping us publish a broad range of topics and timely news updates with information from all oncology disciplines and subspecialties, including hematology, medical, surgical, clinical, and radiation oncology and nursing.
Click here to see a list of the members of the Advisory Board
Join our Editorial Advisory Board
To join our Editorial Advisory Board, Contact us.
Page last updated January 3 , 2013
CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematologic malignancies…is CAR-T therapy what we’ve been waiting for? Join 18+ thought-leaders...